Artificial Intelligence in Eye Care: A Trending Transformation

Artificial intelligence (AI) is becoming more common for screening, diagnosing, and helping treat eye conditions. It is a prominent theme in every industry, but especially within the medical field. Artificial intelligence is advancing quickly and is helping to improve several areas of healthcare.

The annual conference of the Association for Research in Vision and Ophthalmology is taking place from April 23-27, to announce the development of Qdata Geographic Atrophy.

Artificial Intelligence in Healthcare - An Overview
Artificial intelligence (AI) in healthcare is the discipline using data intensive computer based solutions to improve patient care and outcome.

‘Artificial intelligence system is getting trained to predict future eye diseases by simply looking at their retinal images.’

Tweet it Now

This offering provides a comprehensive clinical view of real-world data from almost 350,000 de-identified geographic atrophy (GA) patients, allowing Verena Health to identify GA diagnoses from electronic health records and images for research.

Benefits of Artificial Intelligence (AI) in Screening Eye Diseases

In addition, Voxeleron, a cloud-based ophthalmic image analysis platform provider, announced the results of a study demonstrating its Orion platform, showing that it delivers higher accuracies and reduced variability compared to original equipment manufacturer software from other companies.

The study showed Orion could analyze optical coherence tomography images from other manufacturers and showed greater accuracy with reduced variability, achieving both within a more streamlined workflow.

There is so much potential for AI in healthcare, and companies are starting to realize where to invest their time and money. AI in ophthalmology is important for so many reasons and could be a game changer for many.

Artificial Intelligence to Speed Up Diagnosis of Eye Diseases
Artificial intelligence and machine learning used to develop a new computational tool that can screen patients for blinding eye diseases.

Additionally, the AI-based diagnostic and screening tools provider, Toku, recently received $8m in Series A preferred financing to accelerate the development of its AI-powered technologies for retinal imaging.

Toku plans to use the financing to commercialize AI-powered technologies that are used to analyze retinal images for biometric markers associated with overall health and the risk of cardiovascular events, stroke, and diabetes.

A Problem in Your Eye can Also be a Problem in Your Kidney
Artificial intelligence using certain biomarkers in the eyes can indicate how healthy your kidneys are.

According to GlobalData forecasts, the total AI market will be worth $383.3 billion in 2030, up from $81.3 billion in 2022, having grown at a compound annual growth rate (CAGR) of 21.4%. As it stands, North America and Asia Pacific are the leading AI markets, and regulation will likely hold back AI adoption in Western Europe.

Companies all over the globe and in different industries are viewing AI as a disruptive theme. A recent poll shows that 49% of respondents believe AI will significantly disrupt their industry, and 25% of respondents believe that disruption has already begun.

New Insights into Rare Eye Disorders
Combinations of common gene variants known to be linked to rare eye diseases which include retinal dystrophies change the structure of the retina.

The increasing need for screening eye diseases includes the training and retention of professional graders and optometrists. But the availability of and access to screening services, and the financial sustainability of these screenings in the long run.

These challenges indicate a clear need for a more accurate, efficient, and cost-effective method of detecting diabetic retinopathy. This is where artificial intelligence comes into the picture.

Source-Medindia